A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer

Gastric Cancer

Volumn 15, Issue 1, 2012, Pages 49-55

  Chen, Jen Shi ^a   Chen, Yen Yang ^a   Huang, Jen Sheng ^a   Yeh, Kun Yun ^a   Chen, Ping Tsung ^a   Shen, Wen Chi ^a   Hsu, Hung Chih ^a   Lin, Yung Chung ^a   Wang, Hung Ming ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Chemotherapy; Docetaxel; Gastric cancer; Oxaliplatin

Indexed keywords

DEXAMETHASONE; DOCETAXEL; OXALIPLATIN; SEROTONIN ANTAGONIST;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL FEATURE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CANCER; THROMBOCYTE DISORDER;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84861528221     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0060-2     Document Type: Article

References (27)

1. Parkin DM. Epidemiology of cancer global patterns and trends. Toxicol Lett. 1998;102:227-34. (Pubitemid 29021225)
2. Alberts SR, Cervantes A, Van de Velde CJH. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003; 14(Suppl 2):ii31-6. (Pubitemid 36874136)
3. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;3:CD004064.
4. Pozzo C, Barone C. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? Oncologist. 2008;13:794-806.
5. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs. 1998;55: 5-30. (Pubitemid 28035122)
6. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer. 1994;70:380-3.
7. Nishiyama M, Wada S. Docetaxel: its role in current and future treatment for advanced gastric cancer. Gastric Cancer. 2009;12: 132-41.
8. Van Cutsem E, Moiseyenko VM, Tjulandin S, Tjulandin S, Majlis A, Constenla M, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24:4991-7. (Pubitemid 46631401)
9. Hainsworth JD, Howard AB III, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998; 16:2164-8. (Pubitemid 28265054)
10. Camps C, Massuti B, Jimenez A, Maestu I, Gómez RG, Isla D, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol. 2006;17:467-72. (Pubitemid 43329585)
11. Graziano F, Catalano V, Baldelli AM, Giordani P, Testa E, Lai V, et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol. 2000;11:1263-6.
12. Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev. 2005;31:90-105. (Pubitemid 40542888)
13. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36-46.
14. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435-42.
15. Richards D, McCollum D, Wilfong L, Sborov M, Boehm KA, Zhan F, et al. Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol. 2008;19:104-8.
16. Kim JG, Sohn SK, Chae YS, Song HS, Kwon KY, Do YR, et al. Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group. Br J Cancer. 2008;98: 542-6. (Pubitemid 351214521)
17. Barone C, Basso M, Schinzari G, Pozzo C, Trigila N, D'Argento E, et al. Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. Gastric Cancer. 2007;10:104-11. (Pubitemid 46955936)
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2001;92:205-16.
19. Kim KH, Park YS, Chang MH, Kim HS, Jun HJ, Uhm J, et al. A phase I/II of docetaxel and oxaliplatin in patients with advanced gastric cancer. Cancer Chemother Pharmacol. 2009;64:347-53.
20. Zhong H, Zhang Y, Ma S, Ying JE, Yang Y, Tong D, et al. Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer. Anticancer Drugs. 2008;19(10): 1013-8.
21. Ajani JA. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer. 2008;113:945-55.
22. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007; 5:3217-23. (Pubitemid 47325604)
23. Lo SS, Khorana AA, Javle M, Simon S, Kiefer G, Rajasenan K, et al. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. Oncology. 2010;78:125-9.
24. Jatoi A, Murphy BR, Foster NR, Nikcevich DA, Alberts SR, Knost JA, et al. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol. 2006;17:29-34. (Pubitemid 43033836)
25. Park YH, Kim BS, Ryoo BY, Yang SH. A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer. 2006;94(7): 959-63.
26. Li CP, Chen JS, Chen LT, Yen CJ, Lee KD, Su WP, et al. A phase II study of weekly docetaxel and cisplatin plus oral tegafur/ uracil and leucovorin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Br J Cancer. 2010; 103(9):1343-8.
27. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376:687-97.